2023-09-12 13:26:27 ET
More on Reata Pharmaceuticals
- Seeking Alpha’s Quant Rating on Reata Pharmaceuticals
- Biogen's Bold $7.3B Acquisition Of Reata: Analyzing The Impact On Investors
- Reata: FDA Approval Of SKYCLARYS Isn't Only Driver Moving Forward
- Sanofi was mystery suitor in Reata Pharma bidding war - report
- Biggest stock movers today: Reata Pharmaceuticals, Enphase Energy, Roku and more
- Biogen agrees to buy Reata Pharmaceuticals in deal valued at $7.3B
- TD Cowen starts Reata at outperform, cites sales potential of ataxia drug
For further details see:
Reata Pharmaceuticals climbs as HSR waiting period for sale to Biogen expired